Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22360570 | 0.90 | ACHE (0.49) | ACHEHSD11B1GPBAR1 | |
| SCHEMBL22360569 | 0.83 | ACHE (0.44) | ACHEHSD11B1GPBAR1 | |
| SCHEMBL23766686 | 0.78 | GPBAR1 (0.53) | HSD11B1GPBAR1CA9SLC10A1 | |
| SCHEMBL22360719 | 0.77 | ACHE (0.39) | ACHEHSD11B1F10SLC10A1 | |
| SCHEMBL14083503 | 0.75 | ACHE (0.49) | ACHEHSD11B1SLC10A1 | |
| SCHEMBL12828973 | 0.74 | HSD17B10 (0.49) | ACHEHSD11B1GPBAR1 | |
| SCHEMBL14049657 | 0.74 | HSD17B10 (0.49) | ACHEHSD11B1GPBAR1 | |
| SCHEMBL16433961 | 0.74 | ACHE (0.47) | ACHEHSD11B1F10SLC10A1 | |
| SCHEMBL23766705 | 0.73 | ACHE (0.46) | ACHEHSD11B1GPBAR1 | |
| SCHEMBL13781789 | 0.72 | SLC10A1 (0.51) | ACHEHSD11B1CA9SLC10A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3924361-B1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LTD (IN) | 2023-09-06 | — | — | EP | disclosed |
| WO-2020165741-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2020-08-20 | — | — | WO | disclosed |